Biotechnology

With key clinical data on the horizon for its cancer and ALS drugs, LeonaBio adds deep financial, operational, and strategic expertise to its leadership.

Sesen launches a new platform blending AI and human experts to streamline complex medical translation, aiming for faster, safer global market access.

Vancouver's ME Therapeutics will unveil its in-vivo immune reprogramming technology, a potential cancer treatment game-changer, to global investors.

A massive $250M investment could replace a 40-pill daily burden with a single tablet for patients with pancreatic insufficiency, disrupting a market in crisis.

A leading scientific body is ditching 'longevity' for 'geroscience,' aiming to bring scientific rigor to a field rife with hype and misinformation.

A new drug shows major promise for a painful heart condition, with pivotal study results accepted by a top journal and a final-stage trial speeding ahead.

Quebec biotech firm Aplantex secures $5M to scale its unique green technology, moving from research to industrial production of sustainable ingredients.

With a massive new war chest, the secretive Multi Investment plans to pour capital into fintech, deep tech, and biotech, shaking up innovation funding.

Fueled by a $100M R&D investment, Chinese beauty giant Yatsen is leading a market shift from price wars to scientific innovation, winning global consumers.

Taimei Technology and C&R Research forge a strategic alliance, deploying advanced AI to automate and accelerate drug development in Asia's key research hub.

Diathrive Health and AliveCor's KardiaComplete partner to offer an integrated solution for diabetes and heart disease, combating fragmented care and rising costs.

With a new marketing VP and patented light therapy, medical tech firm Revian is making a strategic play to dominate the booming at-home hair care industry.

A new obesity drug shows 19.3% weight loss with remarkably few side effects, while also improving blood pressure, cholesterol, and even bone density.

From a one-room office to a regional logistics leader, Excel Courier marks four decades of driving critical industries like healthcare and tech.

ABEC's expanded group integrates advanced modeling and custom engineering to accelerate drug development, reduce risk, and boost manufacturing efficiency.

The architect of HUMIRA's launch and Horizon's $28B sale is now shaping the next wave of drug companies from within private equity. What does it mean?

With a promising cancer pipeline, Crescent Biopharma heads to key May conferences to prove its strategy against fierce competition in the bispecific and ADC markets.

As EyePoint's losses widen to fund its lead drug, DURAVYU, the company is on the cusp of pivotal trial results that could redefine retinal disease treatment.

Preclinical data for CITY-RBP4 shows promise in treating Stargardt disease, a leading cause of juvenile blindness with no approved therapies.

A new global partnership aims to solve key bottlenecks in regenerative medicine by providing standardized, high-quality umbilical cord stem cells to researchers.